FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595487159> ?p ?o ?g. }

• W2595487159 endingPage "3833" @default.
• W2595487159 startingPage "3833" @default.
• W2595487159 abstract "Abstract Abstract 3833 Poster Board III-769 Aurora kinases, a family of mitotic regulators, whose expression has been recently linked to genetic instability and cellular proliferation in several cancers including multiple myeloma (MM), are being studied as novel mitotic therapeutic targets. Aurora A plays a crucial role in centrosome separation and spindle assembly and is required for mitosis and bipolar mitotic spindle formation. Aurora B, a member of the chromosomal passenger complex, is required for chromosome segregation, spindle assembly checkpoint and cytokinesis. Both aurora kinase A and B are significantly overexpressed in MM cells prompting the investigation of aurora kinase inhibitors as a therapeutic strategy in MM. Here, we investigated the preclinical activity of a small molecule multi-targeted inhibitor, AT9283, with potent in vitro kinase activity against aurora A and B kinases (3 nM), JAK2 and 3 (at 1.2 and 1.1 nM, respectively) and Abl T315I (at 4 nM). Growth inhibitory effects of AT9283 on MM cell lines and patient derived cells was observed with IC50 values of 0.25μM -0.5 μM at 48 hours using a [3H]-thymidine incorporation assay. Cell cycle analysis following AT9283 treatment resulted in increased G2/M phase and polyploidy consistent with failed cytokinesis (associated with aurora kinase B inhibition) confirmed by immunofluorescence assay. This was followed by induction of apoptosis assessed by Annexin V+PI+ staining peaking at 48 - 72 hours with associated caspase-8/-9 cleavage. The cellular inhibition of aurora kinase activity by AT9283 was confirmed by evaluating the phosphorylation of histone H3 at serine-10, a direct downstream substrate of aurora B kinase. Pretreatment of MM.1S cells with nocodazole, known to induce maximal phosphorylation of histone H3 by causing an M-phase block, resulted in decreased levels of phosphorylated histone H3 after AT9283 treatment suggesting the role of aurora B kinase inhibition by AT9283. Importantly, in addition to aurora kinase inhibition, we observed that AT9283 also inhibited signal transducer and activator of transcription (STAT3) tyrosine phosphorylation in MM cells within 30 minutes of treatment. Janus Kinase (JAK)2/STAT3 pathway is one of the major signaling cascades activated by gp130 family member cytokines that promotes MM cell survival. The effect of AT9283 on pSTAT3 inhibition was further investigated by using U3A cells stably expressing a luciferase reporter gene under the control of a STAT-dependent promoter. AT9283 inhibited STAT3-dependent luciferase activity with an EC50 of approximately 0.125 μM suggesting that STAT3 was functionally inhibited by AT9283. Since MM cell lines with the constitutive STAT3 tyrosine phosphorylation were more sensitive to AT9283, ongoing studies are aimed at understanding whether AT9283-induced effects on the JAK/STAT pathway enhances the efficacy of the aurora kinase inhibition in the context of MM. Finally, in vivo data using a xenograft mouse model of human MM show that mice treated with AT9283 demonstrated slower tumor growth compared to the control group without adverse effects. Our results show pleiotropic effects of AT9283 in MM and warrant further study to determine its suitability for clinical evaluation in MM. Disclosures: Squires: Astex Therapeutics, Ldt: Employment. Yule:Astex Therapeutics Ldt: Employment. Anderson:Novartis, Millennium, Celgene: Consultancy, Honoraria, Research Funding. Raje:Celgene, Norvartis, Astrazeneca: Research Funding." @default.
• W2595487159 created "2017-03-23" @default.
• W2595487159 creator A5005425076 @default.
• W2595487159 creator A5006765393 @default.
• W2595487159 creator A5006954456 @default.
• W2595487159 creator A5009873142 @default.
• W2595487159 creator A5013658453 @default.
• W2595487159 creator A5016860333 @default.
• W2595487159 creator A5019100979 @default.
• W2595487159 creator A5032464400 @default.
• W2595487159 creator A5039965800 @default.
• W2595487159 creator A5041036069 @default.
• W2595487159 creator A5045740077 @default.
• W2595487159 creator A5049134468 @default.
• W2595487159 creator A5052048627 @default.
• W2595487159 creator A5056860535 @default.
• W2595487159 creator A5057460944 @default.
• W2595487159 creator A5067330530 @default.
• W2595487159 creator A5083655413 @default.
• W2595487159 creator A5090686439 @default.
• W2595487159 creator A5091207345 @default.
• W2595487159 date "2009-11-20" @default.
• W2595487159 modified "2023-09-30" @default.
• W2595487159 title "AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition." @default.
• W2595487159 doi "https://doi.org/10.1182/blood.v114.22.3833.3833" @default.
• W2595487159 hasPublicationYear "2009" @default.
• W2595487159 type Work @default.
• W2595487159 sameAs 2595487159 @default.
• W2595487159 citedByCount "1" @default.
• W2595487159 countsByYear W25954871592013 @default.
• W2595487159 crossrefType "journal-article" @default.
• W2595487159 hasAuthorship W2595487159A5005425076 @default.
• W2595487159 hasAuthorship W2595487159A5006765393 @default.
• W2595487159 hasAuthorship W2595487159A5006954456 @default.
• W2595487159 hasAuthorship W2595487159A5009873142 @default.
• W2595487159 hasAuthorship W2595487159A5013658453 @default.
• W2595487159 hasAuthorship W2595487159A5016860333 @default.
• W2595487159 hasAuthorship W2595487159A5019100979 @default.
• W2595487159 hasAuthorship W2595487159A5032464400 @default.
• W2595487159 hasAuthorship W2595487159A5039965800 @default.
• W2595487159 hasAuthorship W2595487159A5041036069 @default.
• W2595487159 hasAuthorship W2595487159A5045740077 @default.
• W2595487159 hasAuthorship W2595487159A5049134468 @default.
• W2595487159 hasAuthorship W2595487159A5052048627 @default.
• W2595487159 hasAuthorship W2595487159A5056860535 @default.
• W2595487159 hasAuthorship W2595487159A5057460944 @default.
• W2595487159 hasAuthorship W2595487159A5067330530 @default.
• W2595487159 hasAuthorship W2595487159A5083655413 @default.
• W2595487159 hasAuthorship W2595487159A5090686439 @default.
• W2595487159 hasAuthorship W2595487159A5091207345 @default.
• W2595487159 hasConcept C10447061 @default.
• W2595487159 hasConcept C141937037 @default.
• W2595487159 hasConcept C1491633281 @default.
• W2595487159 hasConcept C153911025 @default.
• W2595487159 hasConcept C175732170 @default.
• W2595487159 hasConcept C184235292 @default.
• W2595487159 hasConcept C185592680 @default.
• W2595487159 hasConcept C190283241 @default.
• W2595487159 hasConcept C20552341 @default.
• W2595487159 hasConcept C2779425043 @default.
• W2595487159 hasConcept C2780808130 @default.
• W2595487159 hasConcept C29537977 @default.
• W2595487159 hasConcept C3453395 @default.
• W2595487159 hasConcept C45472230 @default.
• W2595487159 hasConcept C47432576 @default.
• W2595487159 hasConcept C502942594 @default.
• W2595487159 hasConcept C55493867 @default.
• W2595487159 hasConcept C85813293 @default.
• W2595487159 hasConcept C86803240 @default.
• W2595487159 hasConcept C93304396 @default.
• W2595487159 hasConcept C95444343 @default.
• W2595487159 hasConceptScore W2595487159C10447061 @default.
• W2595487159 hasConceptScore W2595487159C141937037 @default.
• W2595487159 hasConceptScore W2595487159C1491633281 @default.
• W2595487159 hasConceptScore W2595487159C153911025 @default.
• W2595487159 hasConceptScore W2595487159C175732170 @default.
• W2595487159 hasConceptScore W2595487159C184235292 @default.
• W2595487159 hasConceptScore W2595487159C185592680 @default.
• W2595487159 hasConceptScore W2595487159C190283241 @default.
• W2595487159 hasConceptScore W2595487159C20552341 @default.
• W2595487159 hasConceptScore W2595487159C2779425043 @default.
• W2595487159 hasConceptScore W2595487159C2780808130 @default.
• W2595487159 hasConceptScore W2595487159C29537977 @default.
• W2595487159 hasConceptScore W2595487159C3453395 @default.
• W2595487159 hasConceptScore W2595487159C45472230 @default.
• W2595487159 hasConceptScore W2595487159C47432576 @default.
• W2595487159 hasConceptScore W2595487159C502942594 @default.
• W2595487159 hasConceptScore W2595487159C55493867 @default.
• W2595487159 hasConceptScore W2595487159C85813293 @default.
• W2595487159 hasConceptScore W2595487159C86803240 @default.
• W2595487159 hasConceptScore W2595487159C93304396 @default.
• W2595487159 hasConceptScore W2595487159C95444343 @default.
• W2595487159 hasIssue "22" @default.
• W2595487159 hasLocation W25954871591 @default.
• W2595487159 hasOpenAccess W2595487159 @default.
• W2595487159 hasPrimaryLocation W25954871591 @default.
• W2595487159 hasRelatedWork W1535915839 @default.
• W2595487159 hasRelatedWork W1657816165 @default.

• next